FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment

Psychiatry Res. 2007 Jul 15;155(2):167-71. doi: 10.1016/j.pscychresns.2006.12.002. Epub 2007 May 24.

Abstract

Specific patterns of cortical glucose metabolism disturbances and increased CSF phospho-tau (p-tau(181)) concentrations could be demonstrated to predict cognitive decline and shift to dementia in amnestic mild cognitive impairment (MCI). But comparisons of both diagnostic tools have not been undertaken so far. The aim of the study was to compare (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) findings and CSF phospho-tau (p-tau(181)) measurements in the prediction of cognitive deterioration and conversion to dementia in MCI. During follow-up (mean 19 months) eight of 16 patients (50%) showed progressive cognitive decline, and four patients shifted to dementia. Pathological FDG-PET and elevated p-tau(181) levels both predicted deterioration. While p-tau(181) was highly sensitive for cognitive decline, FDG-PET was superior in predicting conversion to clinical dementia in MCI patients.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Biomarkers / cerebrospinal fluid
  • Cognition Disorders / cerebrospinal fluid
  • Cognition Disorders / diagnosis*
  • Cognition Disorders / diagnostic imaging
  • Dementia / diagnosis
  • Female
  • Fluorodeoxyglucose F18*
  • Follow-Up Studies
  • Humans
  • Image Processing, Computer-Assisted
  • Imaging, Three-Dimensional
  • Kaplan-Meier Estimate
  • Longitudinal Studies
  • Male
  • Mental Status Schedule
  • Positron-Emission Tomography / methods
  • Positron-Emission Tomography / statistics & numerical data*
  • Prognosis
  • Psychiatric Status Rating Scales
  • Severity of Illness Index
  • Stereotaxic Techniques
  • tau Proteins / cerebrospinal fluid*

Substances

  • Biomarkers
  • tau Proteins
  • Fluorodeoxyglucose F18